Hong Wan
Chief Executive Officer & Co-Founder Tallac Therapeutics
Seminars
Tuesday 4th November 2025
Employing Novel Immune Modulating Payload to Achieve Differentiation: Assessing TRAAC Clinical Validation
2:30 pm
- Highlighting the novel immune- stimulating payload and unique site-specific conjugation employed in TRAACs
- Case study of TAC-001: navigating preclinical to clinical translation of payload MoA
- Exploring development of TAC-003, a novel payload leading to differentiation versus conventional ADCs with the same target
